Haemonetics (HAE) Research & Development (2009 - 2026)

Haemonetics has reported Research & Development for 18 years, with the latest figure at $16.2 million in Q2 2026.

• On a quarterly basis, Research & Development changed 0.38% year-over-year to $16.2 million in Q2 2026; TTM through Jun 2026 was $59.7 million, a 7.48% decrease from a year earlier, with the FY2026 full-year figure at $59.8 million, down 4.71% from the prior year.
• Research & Development was $16.2 million for Q2 2026 at Haemonetics, up from $14.4 million in the prior quarter.
• The five-year high for Research & Development was $18.3 million in Q1 2025, with the low at $10.0 million in Q1 2022.
• Average Research & Development over 5 years is $14.0 million, with a median of $14.2 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2026: Research & Development soared 33.81% in 2022, then fell 21.08% in 2026.
• Over 5 years, Research & Development stood at $12.7 million in 2022, then rose by 4.54% to $13.3 million in 2023, then gained by 19.33% to $15.8 million in 2024, then declined by 10.37% to $14.2 million in 2025, then advanced by 14.19% to $16.2 million in 2026.
• The last three Research & Development figures came in at $16.2 million (Q2 2026), $14.4 million (Q1 2026), and $14.2 million (Q4 2025), per Business Quant data.